Plain-English translation of NCT06887348 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This is a follow-up study for patients who have already received Replimune oncolytic immunotherapy (RP1, RP2, or RP3) in a previous trial. Researchers want to check in with you regularly over the next 5 years to watch for any delayed side effects that might develop after treatment, such as new cancers, infections, or autoimmune problems. No new medications or treatments will be given in this study—it's purely about monitoring your health.
Cancer treatments can sometimes cause side effects that appear months or years later. This medication is still relatively new, so researchers need to carefully track long-term safety in patients who have received it to make sure it remains safe and to catch any problems early.
You likely qualify if…
You likely don't qualify if…
You will receive a phone call from the research team every 3 months for 5 years. During these calls, they will ask you questions about your health, any new symptoms, infections, or concerns since your treatment. If you develop any signs of a herpetic infection, you may be asked to provide a swab sample or blood/urine samples so researchers can check if they are related to the treatment. All check-ins can happen by phone, video call, or in person—whatever is easiest for you.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Australia